Who are Placebo to Tolterodine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Solifenacin for 24 weeks, Toviaz (Fesoterodine), Spiriva HandiHaler, Solifenacin succinate treatment, Solifenacin PO, Drug: ipratropium (AtroventTM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-tolterodine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to Tolterodine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Tolterodine (Placebo to Tolterodine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic M3 receptor antagonist. Area: Urology.

phase 3 Muscarinic M3 receptor antagonist M3 muscarinic acetylcholine receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Tolterodine (Placebo to Tolterodine) — Astellas Pharma Inc. Tolterodine is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Tolterodine TARGET	Placebo to Tolterodine	Astellas Pharma Inc	phase 3	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Solifenacin for 24 weeks	Solifenacin for 24 weeks	National Taiwan University Hospital	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Toviaz (Fesoterodine)	Toviaz (Fesoterodine)	Weill Medical College of Cornell University	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Spiriva HandiHaler	Spiriva HandiHaler	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic acetylcholine receptor
Solifenacin succinate treatment	Solifenacin succinate treatment	Barrie Urology Associates	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Solifenacin PO	Solifenacin PO	Seattle Urology Research Center	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Drug: ipratropium (AtroventTM)	Drug: ipratropium (AtroventTM)	AstraZeneca	marketed	Anticholinergic bronchodilator	M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic M3 receptor antagonist class)

Astellas Pharma Inc · 2 drugs in this class
Barrie Urology Associates · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Pfizer · 1 drug in this class
Seattle Urology Research Center · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Tolterodine — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-tolterodine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab